Singapore-based advanced analytics and artificial intelligence specialist LynxKite Technologies Pte Ltd announced on Friday that it is expanding its partnership with Biophytis SA (Euronext Growth Paris:ALBPS), a clinical-stage biotechnology company based in France.

The collaboration will start with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy), with plans to expand the platform to other modalities. This strategic initiative, also supported by Enterprise Singapore, is aligned with priority target areas in Singapore's Research, Innovation and Enterprise (RIE) 2030 plan.

LynxKite Technologies will integrate AI computational methods relevant for longevity research into its computational orchestration platform. The founding team of LynxKite has supported more than 100 global enterprises -- including major players such as Roche, AstraZeneca and Hummingbird Biosciences -- in analysing complex data using graph-based and generative AI approaches.

The first MASSIVE project aims to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia, a degenerative muscle disease associated with ageing that affects millions of elderly people worldwide. Biophytis contributes its deep expertise in age-related diseases, its preclinical experience in MasR-linked indications, and its expertise in Mas receptor pharmacology, while LynxKite brings state-of-the-art AI technologies, chemoinformatics, and software engineering coupled with scaling GPU computation on the latest generation of NVIDIA toolkits and neoclouds such as Nebius. Together, the partners strengthen Biophytis' strategic drug discovery programme, aligned with its longevity-focused strategy and positioning.